HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Abroad (travel likely)RecruitingPHASE2
Conditions
Fanconi Anemia · Severe Marrow Failure · Myelodysplastic Syndrome (MDS) · Acute Myelogenous Leukemia (AML)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Contact: Principal Investigator (Parinda Mehta, MD)Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Contact: Principal Investigator (K. Scott Baker, MD)
Study leads
Parinda Mehta, MD
Principal Investigator
CCHMC